- Home
- KIDS vs AUTL Comparison
KIDS vs AUTL Comparison
Compare KIDS & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIDS
- AUTL
- Stock Information
- Founded
- KIDS 2007
- AUTL 2014
- Country
- KIDS United States
- AUTL United Kingdom
- Employees
- KIDS N/A
- AUTL N/A
- Industry
- KIDS Medical/Dental Instruments
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KIDS Health Care
- AUTL Health Care
- Exchange
- KIDS Nasdaq
- AUTL Nasdaq
- Market Cap
- KIDS 526.1M
- AUTL 625.4M
- IPO Year
- KIDS 2017
- AUTL 2018
- Fundamental
- Price
- KIDS $22.16
- AUTL $2.63
- Analyst Decision
- KIDS Buy
- AUTL Strong Buy
- Analyst Count
- KIDS 7
- AUTL 5
- Target Price
- KIDS $35.71
- AUTL $9.32
- AVG Volume (30 Days)
- KIDS 128.7K
- AUTL 1.8M
- Earning Date
- KIDS 08-04-2025
- AUTL 08-07-2025
- Dividend Yield
- KIDS N/A
- AUTL N/A
- EPS Growth
- KIDS N/A
- AUTL N/A
- EPS
- KIDS N/A
- AUTL N/A
- Revenue
- KIDS $212,453,000.00
- AUTL $9,011,000.00
- Revenue This Year
- KIDS $19.23
- AUTL $461.76
- Revenue Next Year
- KIDS $17.14
- AUTL $112.66
- P/E Ratio
- KIDS N/A
- AUTL N/A
- Revenue Growth
- KIDS 31.28
- AUTL N/A
- 52 Week Low
- KIDS $19.52
- AUTL $1.11
- 52 Week High
- KIDS $35.99
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- KIDS 52.66
- AUTL 69.63
- Support Level
- KIDS $21.17
- AUTL $2.40
- Resistance Level
- KIDS $22.76
- AUTL $2.52
- Average True Range (ATR)
- KIDS 0.81
- AUTL 0.11
- MACD
- KIDS 0.09
- AUTL -0.00
- Stochastic Oscillator
- KIDS 70.00
- AUTL 85.97
About KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.